A method for the prevention of hypoglycaemia in diabetes mellitus type 2 comprising administering (a) desPro36 Exenden-4(1-39)-Lys6-NH2 AV0010, ZP-10A, lixisenatide or/and a pharmaceutically acceptable salt thereof, and (b)a sulfonyl urea or/and pharmaceutically acceptable salt thereof, to a subject in need thereof. A pharmaceutical combination comprising desPro36 Exenden-4(1-39)-Lys6-NH2 or/and a pharmaceutically acceptable salt thereof, particularly for subcutaneous administration, and a sulfonyl urea or/and pharmaceutically acceptable salt thereof, particularly for oral administration and optionally metrormin or/and a pharmaceutically acceptable salt thereof, particularly for oral administration.
